Epibiotech

Epibiotech is a South Korean biopharmaceutical company specializing in the development of innovative treatments for alopecia. The company leverages a proprietary AI-driven drug discovery platform, Hair.I., which integrates a large genomic database, single-cell analysis, and AI screening to identify novel hair loss targets. Their research focuses on advanced modalities, including autologous and allogeneic dermal papilla cell therapies and neutralizing antibody treatments, designed to stimulate hair follicle regeneration and address the underlying causes of hair loss such as androgenetic factors.

These therapeutics provide targeted solutions for patients suffering from hair loss, aiming to offer more effective, science-based restoration compared to conventional treatments. By combining its drug development pipeline with non-clinical CRO expertise for efficacy evaluation, Epibiotech supports the advancement of hair science from discovery to clinical trials. The company has reached significant milestones, including initiating clinical trials for its lead cell therapy candidate, EPI-001, and securing recognition through international biotech innovator awards.